HPV cervical CA screening cuts odds of later CIN3+ diagnosis

July 4, 2018

(HealthDay)—The use of primary human papillomavirus (HPV) testing versus cytology results in reduced likelihood of cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) at 48 months, according to a study published in the July 3 issue of the Journal of the American Medical Association.

Gina Suzanne Ogilvie, M.D., from the University of British Columbia in Vancouver, Canada, and colleagues conducted a randomized trial to assess histologically confirmed cumulative incident CIN3+ detected up to and including 48 months by HPV testing alone or liquid-based cytology. Overall, 19,009 women were randomized to the intervention and control groups (9,552 and 9,457, respectively). Women in the intervention received HPV testing, while those in the control group received liquid-based cytology testing.

Overall, 8,296 and 8,078 in the intervention and control groups, respectively, completed the study. The researchers found that significantly fewer CIN3+ and CIN2+ were detected in the intervention versus the at 48 months. Per 1,000 women, the incidence rates were 2.3 and 5.5 for CIN3+ in the intervention and control groups, respectively; the corresponding rates for CIN2+ were 5.0 and 10.6 (risk ratios, 0.42 and 0.47).

"Among women undergoing cervical cancer screening, the use of primary HPV testing compared with cytology testing resulted in a significantly lower likelihood of CIN3+ at 48 months," the authors write. "Further research is needed to understand long-term clinical outcomes as well as cost-effectiveness."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Low incidence of cervical cancer, CIN3+ for HPV-negative women

More information: Abstract/Full Text
Editorial (subscription or payment may be required)

Related Stories

Low incidence of cervical cancer, CIN3+ for HPV-negative women

October 7, 2016
(HealthDay)—Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+), which supports an extension of the cervical screening ...

Risk of CIN3 drops with negative HPV, cytology co-tests

November 28, 2017
(HealthDay)—The five-year risks of cervical intraepithelial neoplasia grade 3 (CIN3), adenocarcinoma in situ, and cervical cancer (≥CIN3) decrease after each successive negative human papillomavirus (HPV) and cytology ...

Screening for cervical abnormalities in women offered HPV vaccination

September 19, 2017
Human papillomavirus (HPV) testing detects a higher number of precancerous cervical lesions than cytology-based Pap smears in a female population including a proportion offered HPV vaccination, according to a new study published ...

Risk of noncervical anogenital cancer up with history of CIN2/3

July 6, 2016
(HealthDay)—Women with a history of cervical intraepithelial neoplasia (CIN)2 or CIN3 have increased risks of subsequent development of anal, vulvar, and vaginal cancers, according to a study published online June 29 in ...

HIV-seropositive CIN3+ patients have lower HPV16 prevalence

March 16, 2016
(HealthDay)—HIV-seropositive women with cervical intraepithelial neoplasia (CIN) grade ≥3 (CIN3+) are less likely to have human papillomavirus (HPV) 16, according to a study published in the March issue of the American ...

Recommended for you

Fusion hybrids: A newly discovered population of tumor cells

September 24, 2018
In a recent study published in Science Advances, Charles E. Gast and co-workers detail the spontaneous process of cancer cell fusion with white blood cells to produce heterogenous hybrid clones in multiple biological systems, ...

Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse

September 24, 2018
Harnessing the immune system to treat cancer shows great promise in some patients, but for many, the response does not last long-term. In an effort to find out why, Fred Hutchinson Cancer Research Center scientists are using ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.